|  |
| --- |
| For best navigation, click on the table of contents to navigate and click on and header or subheader to return to the table of contents. Otherwise, use the Document Outline feature (to the left on PC, or the top right ellipsis drop-down menu on the mobile app).  **This document is a collaborative resource. Contributions welcome!** We tried to focus on brief, high yield articles as much as possible.  Click on any information within [brackets] for a direct link to PubMed.  **Education Resources, General Contouring and Planning, and Accessible Protocols are available for members at** [**http://www.acro.org/**](http://www.acro.org/) |

We need your help! Please contribute articles that communicate the overarching themes of disease sites.

All articles are subject to be changed or replaced if better options are contributed by users. Limit to < 10 per disease site.

Commentary should be open to all users, with final changes approved by administrators.

# Table of Contents

[Introduction](#_6xz6equymzi2) 2

[Palliative](#_ih4g8gp3tywi) 2

[Immunotherapy](#_pebj8xdi1pj7) 2

[Oligometastases](#_7t93ursyzgz5) 2

[Brain Mets](#_85b8zkeb3oiv) 2

[Breast](#_t3v2zt28uzvy) 2

[CNS](#_u7oz3e11i8xz) 3

[Peds](#_m5nq7nc7r13g) 3

[Constraints / Toxicity](#_4t5jsm6nukqp) 4

[GI](#_qhhz7w5us2kb) 4

[Gyn](#_iaarw656jw1h) 4

[Non-Prostate GU](#_llljm3s07bal) 5

[GU](#_3yl3qibnuyep) 5

[H&N, Thyroid](#_hxgynw3nndo8) 5

[Skin](#_sboty56iccrw) 6

[Heme](#_o9yj8xhc9dfq) 6

[Rad Phys and Rad Bio](#_3wbuzpdn8nst) 6

[Sarcoma / Musculoskeletal](#_6hgxjf70ejhv) 6

[Thorax](#_315mdh48hv86) 7

[Misc](#_2hx9zwidenuh) 7

## 

## Introduction

* Standardizing Normal Tissue Contouring ASTRO Consensus (Table E1 & E2) [[Wright PRO '19]](https://www.ncbi.nlm.nih.gov/pubmed/30576843)
* How Path and Recurrence Patterns Inform CTV [[Chharbra Semin Rad Onc '18]](https://www.ncbi.nlm.nih.gov/pubmed/29933882)
* CB-CHOP plan evaluation system: [[Dean Applied Rad Onc]](https://appliedradiationoncology.com/articles/cb-chop-a-simple-acronym-for-evaluating-a-radiation-treatment-plan)

## [Palliative](#_xfnv5f4m7q1m)

* Center to Advance Palliative care: [www.capc.org](http://www.capc.org)
* Serious illness conversation guide [[Here](https://www.ariadnelabs.org/wp-content/uploads/sites/2/2017/05/SI-CG-2017-04-21_FINAL.pdf)]: SPIKES [[Baile Oncologist '00](https://www.ncbi.nlm.nih.gov/pubmed/32278982)]. [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#heading=h.8nc46pa2rglq)
* When nothing is the right thing to say [[Morgan BMJ '20](https://www.bmj.com/content/368/bmj.m574)] [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#heading=h.8nc46pa2rglq)
* 'An Emotional Slap in the Face': The Language of Cancer [[Dizon and Prowell Medscape '19](https://www.medscape.com/viewarticle/914359?src=soc_tw_190618_mscpedt_news_mdscp_bedsidemanner&faf=1#vp_1)] [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#heading=h.8nc46pa2rglq)

## 

## [Immunotherapy](#_xfnv5f4m7q1m)

* The Promise of Combining RT with Immunotherapy [[Jagodinsky IJROBP '20](https://www.ncbi.nlm.nih.gov/pubmed/32335187)] [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#bookmark=id.veosfpakhcll)
* The emerging role of PTEN loss in evasion of the immune response to tumors (Figs 1, 2) [[Vidotto BJC '20](https://www.ncbi.nlm.nih.gov/pubmed/32327707)] [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#bookmark=id.veosfpakhcll)
* A Review of Cancer Immunotherapy Toxicity[[Kennedy CA Can J Clin '20](https://www.ncbi.nlm.nih.gov/pubmed/31944278)] [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#bookmark=id.i0wst9hgrnp4)
* Predictors of response to Immunotherapy, from most to least important[[Lee JAMA Onc '19](https://jamanetwork.com/journals/jamaoncology/fullarticle/2748890)]  
  TBL [QS](http://www.quadshotnews.com/2019/08/axis-powers.html): It’s likely we’ll see more complex “triple axis” immunotherapy panels in the future that more accurately predict ICI response. Triple axis = immune cell infiltrate, tumor neoantigens, and checkpoint targets.

1. Tumor microenvironment (pretreatment CD8+ T cells) within the tumor.
2. Tumor neoantigens (High mutational burden) also portends to a better response.
3. Checkpoint targets (PD-L1 protein expression) alone is a poor predictor of response to ICI.

* CAR T Cells: Continuation in a revolution of immunotherapy [QS](http://www.quadshotnews.com/2020/03/horse-before-cart.html) [[Singh Lanc Onc '20](https://www.ncbi.nlm.nih.gov/pubmed/32135120)]
* Radiation and ICI: Radiosensitization and potential mechanisms of synergy [[Sharabi Lanc Onc '15](https://www.ncbi.nlm.nih.gov/pubmed/26433823)] [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#bookmark=id.i0wst9hgrnp4)
* Lung SBRT and Concurrent Immunotherapy [[Tian IJROBP '20](https://www.ncbi.nlm.nih.gov/pubmed/31982496)]: SBRT ± ICI. [RoR](https://docs.google.com/document/d/1oKD3L5ieCk03FWU6fCnj8aiHKRPJD-q6IpjXpQCuexw/edit#bookmark=id.70uud96bc7wd)

## [Oligometastases](#_xfnv5f4m7q1m)

* Stereotactic Radiotherapy of Malignancies in the Abdomen [[Lax Acta Oncologica '94](https://www.ncbi.nlm.nih.gov/pubmed/7946448)] [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#heading=h.uaty9bc8mcj4)
* Stereotactic High Dose Fraction RT of Extracranial Tumors using an Accelerator [[Blomgren Acta Oncologica '95](https://www.tandfonline.com/doi/pdf/10.3109/02841869509127197)] [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#heading=h.uaty9bc8mcj4)
* "Oligometastases" is coined! [[Hellman and Weichselbaum JCO '95](https://www.ncbi.nlm.nih.gov/pubmed/7799047)] [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#heading=h.uaty9bc8mcj4)
* RPA for Oligometastatic NSCLC [[Ashworth CLC '14](https://www.sciencedirect.com/science/article/pii/S1525730414000771)]: Metachronous vs. Synchronous, N0 vs. Synchronous, N+.
* The Dandelion Dilemma for Oligoprogression: Treat the Whole Lawn or Weed Selectively? [[Patel Clin Onc '19](https://www.ncbi.nlm.nih.gov/pubmed/31182289)] [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#heading=h.ig84j8lvm4zv)
* Oligo Review of NSCLC Oligometastases [[Giulani IJROBP '20](https://www.ncbi.nlm.nih.gov/pubmed/32014142)] [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#heading=h.sfi9w935mota)
* Oligometastases: History of a hypothesis [[Milano Ann Palliative Medicine '20](https://www.ncbi.nlm.nih.gov/pubmed/32279519)]
* Curing Metastatic Disease with Ablative RT: Separating Truth from Wish [[Kamran and Zietman IJROBP '20](https://pubmed.ncbi.nlm.nih.gov/32531389/)].
* Curing Metastatic Disease with RT: Myth or Reality? Arguing for Reality [[Rahimi and Timmerman IJROBP '20](https://pubmed.ncbi.nlm.nih.gov/32531388/)].

## 

## [Brain Mets](#_xfnv5f4m7q1m)

eContour: [[Intact brain mets](http://econtour.org/cases/100)].

* GPA Index: [www.brainmetgpa.com](http://www.brainmetgpa.com). The most up to date values! Bookmark this app on your phone. Last update in 2017. [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#bookmark=id.qrx6lzypx4a5)
* NRG CC001 [[Commentary](https://www.ascopost.com/issues/december-10-2018/hippocampus-sparing-wbrt-and-neurocognitive-function-in-patients-with-brain-metastases/)]: 6 mo Memantine + 30/10 ± HA. [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#bookmark=id.fnhdj8o51q84)
* Current multidisciplinary management of brain metastases [[Moravan Cancer '20](https://www.ncbi.nlm.nih.gov/pubmed/31971613)]. [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#bookmark=id.focksuac7esp)
* Local recurrence patterns after postoperative SRS to resected brain metastasis [[Gui PRO '18](https://www.ncbi.nlm.nih.gov/pubmed/30029965)]: Retro. Post-op SRS. [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#bookmark=id.9j8m9vqex8rc)
* Comparison of SRS modalities [[Vergalasova Frontiers Oncology '19](https://www.frontiersin.org/articles/10.3389/fonc.2019.00483/full)] [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#bookmark=id.15ubv1c929su)
* SRS for Resected Brain mets - Does the Surgical Corridor need to be targeted? [[Shi PRO '20](https://pubmed.ncbi.nlm.nih.gov/32428766/)]: Retro. ± Corridor.

## 

## [Breast](#_xfnv5f4m7q1m)

Zaorsky: [[simplified mammography diagram](https://twitter.com/NicholasZaorsky/status/1211646810676064258)], [[mammography interpretations](https://twitter.com/NicholasZaorsky/status/1212008844198592513)], [[lymph node stations](https://twitter.com/NicholasZaorsky/status/1211701256412172288)], [[atlas](https://twitter.com/NicholasZaorsky/status/1211727554299809792)], [[nodal couch kick](https://twitter.com/NicholasZaorsky/status/1211702308649799681)] and [[field matching](https://twitter.com/NicholasZaorsky/status/1211705635424718848)].

ARRO: [[APBI case](https://www.astro.org/uploadedFiles/Affiliates/ARRO/Resident_Resources/Educational_Resources/Case_Vingettes/APBI.pdf), [contour](https://www.astro.org/uploadedFiles/Affiliates/ARRO/Resident_Resources/Educational_Resources/Case_Vingettes/APBI_Contour.pdf)], [[DCIS case](https://www.astro.org/uploadedFiles/DCIS.pdf), [contour](https://www.astro.org/uploadedFiles/DCISContour.pdf)], [[Inflammatory breast cancer](https://www.astro.org/uploadedFiles/Affiliates/ARRO/Resident_Resources/Educational_Resources/Case_Vingettes/InflammatoryBreast.pdf)], [[Radiation indications in the setting of NAC](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/NeoadjuvantchemoBreastCancer.pdf)].

eContour [[early breast cancer](https://econtour.org/cases/73)], [[regional nodal irradiation](https://econtour.org/cases/74)], [[PMRT](https://econtour.org/cases/75)], [[heart avoidance]](http://econtour.org/cases/73).

eContour hypofractionation: [[MSKCC PBI](http://econtour.org/cases/108)], [[UK Fast Forward](http://www.econtour.org/cases/117)], [[Florence](http://econtour.org/cases/47)] and [[RT CHARM](http://econtour.org/cases/110)].

* **JCO Special Series:** Multi-D Locoregional Management of Breast Cancer [QS](http://www.quadshotnews.com/2020/06/special-delivery.html)[[Smith, Mittendorf and Haffty JCO '20](https://ascopubs.org/doi/full/10.1200/JCO.20.00483)]. [RoR](https://docs.google.com/document/d/1sWQwqcSH23B30CKCVOaQ2kb4D4qES6YfPqmgJYR5rnY/edit#bookmark=id.m2eo74vcdjvv)
* Bernard Fisher: 1918-2019 [[Wolmark JCO '20](https://www.ncbi.nlm.nih.gov/pubmed/32286901)] [RoR](https://docs.google.com/document/d/1sWQwqcSH23B30CKCVOaQ2kb4D4qES6YfPqmgJYR5rnY/edit#bookmark=id.lo7ae5d744xf)
* The Landmark Series: Adjuvant RT for Breast Cancer [[Valente & Shah, Surg Onc '20](https://www.ncbi.nlm.nih.gov/pubmed/32314162)] [RoR](https://docs.google.com/document/d/1sWQwqcSH23B30CKCVOaQ2kb4D4qES6YfPqmgJYR5rnY/edit#bookmark=id.ijj8zfg3uj39)
* An Overview of the NSABP Trials [[50 years of NSABP](https://www.ctsu.ox.ac.uk/research/the-early-breast-cancer-trialists-collaborative-group-ebctcg/previous-findings)]. [RoR](https://docs.google.com/document/d/1sWQwqcSH23B30CKCVOaQ2kb4D4qES6YfPqmgJYR5rnY/edit#heading=h.tnkj36sl1zgt)
* Previous Findings from EBCTCG [[Website](https://www.ctsu.ox.ac.uk/research/the-early-breast-cancer-trialists-collaborative-group-ebctcg/previous-findings)]. [RoR](https://docs.google.com/document/d/1sWQwqcSH23B30CKCVOaQ2kb4D4qES6YfPqmgJYR5rnY/edit#heading=h.82m26dr3iu6o)
* Management of the cN0, pN+ Axilla in Breast Cancer in 2017 [[Morrow JAMA Onc '18](https://jamanetwork.com/journals/jamaoncology/fullarticle/2665748)] [RoR](https://docs.google.com/document/d/1sWQwqcSH23B30CKCVOaQ2kb4D4qES6YfPqmgJYR5rnY/edit#heading=h.ja7mbv9tjlmf)
  + Wonderful two-page summary article on what to do with SLNs in the setting of clinically negative axilla.
  + Long story short, most patients with ≤ 2 SLN may avoid and axillary lymph node dissection.
  + All patients who are cN+ should get ALND unless enrolled in a clinical trial.
* Radiotherapy in the setting of breast reconstruction: types, techniques, and timing [[Ho Lancet Onc '17]](https://www.sciencedirect.com/science/article/pii/S1470204517306174?via%3Dihub) [RoR](https://docs.google.com/document/d/1sWQwqcSH23B30CKCVOaQ2kb4D4qES6YfPqmgJYR5rnY/edit#heading=h.qmtzz7lgjk35)
* Inflammatory Breast Cancer: The MDACC approach [[Stecklein PRO '19](https://www.sciencedirect.com/science/article/pii/S1879850019301420)]. [RoR](https://docs.google.com/document/d/1sWQwqcSH23B30CKCVOaQ2kb4D4qES6YfPqmgJYR5rnY/edit#heading=h.omzse5sy3eew)
* DCIS: To Boost or Not to Boost? Extrapolation from invasive disease [[Moran JAMA Oncol '17]](https://jamanetwork.com/journals/jamaoncology/fullarticle/2613411):Retro. ± boost. [RoR](https://docs.google.com/document/d/1sWQwqcSH23B30CKCVOaQ2kb4D4qES6YfPqmgJYR5rnY/edit#bookmark=id.h7h1guhmrp33)
* RT without endocrine therapy for women age 70+ [[Ward IJROBP '19](https://www.sciencedirect.com/science/article/pii/S0360301619308491?via%3Dihub)]: Anastrozole x5y vs. 40/15 WBRT. [RoR](https://docs.google.com/document/d/1sWQwqcSH23B30CKCVOaQ2kb4D4qES6YfPqmgJYR5rnY/edit#bookmark=id.81qc2yfdoqim)
* EBCTCG 20y risks of breast cancer recurrence after stopping endocrine therapy at 5y [QS](http://www.quadshotnews.com/2017/11/roy-moore-louis-ck-and-tamoxifen.html) [[Pan NEJM '17]](https://www.nejm.org/doi/10.1056/NEJMoa1701830?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dwww.ncbi.nlm.nih.gov) [RoR](https://docs.google.com/document/d/1sWQwqcSH23B30CKCVOaQ2kb4D4qES6YfPqmgJYR5rnY/edit#bookmark=id.82zqrt8uc9jh)

## 

## [CNS](#_xfnv5f4m7q1m)

eContour: [[GBM](http://econtour.org/cases/116)], [[LGG](http://econtour.org/cases/101)], [[Meningioma](http://econtour.org/cases/102)], [[Recurrent pituitary adenoma](http://econtour.org/cases/93)], [[Vestibular schwannoma](http://econtour.org/cases/92)].

Zaorsky: [[MRI characteristics of brain lesions](https://twitter.com/NicholasZaorsky/status/1211367193654562816)], [[Pseudoprogression vs. radiation necrosis](https://twitter.com/NicholasZaorsky/status/1211368296693538818)], [[RANO criteria for GBM recurrence](https://twitter.com/NicholasZaorsky/status/1211369359047827456)].

ARRO: [[GBM-PNET](https://www.astro.org/ASTRO/media/ASTRO/AffiliatePages/arro/PDFs/ARROCase_GBMPNET.pdf)], [[GBM](https://www.astro.org/ASTRO/media/ASTRO/AffiliatePages/arro/PDFs/ARROcase_GBM.pdf)], [[Glioblastoma Multiforme (GBM) Case](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/ARROCASEGMB(1).pdf), [Contour](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/ARROContourGBM.pdf)], [[Low Grade Glioma (LGG)](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/ARROCase-Low-Grade-Glioma.pdf)].

Zaorsky: [[General MRI characteristics of brain lesions](https://twitter.com/NicholasZaorsky/status/1211367193654562816)], [[Pseudoprogression vs. radiation necrosis](https://twitter.com/NicholasZaorsky/status/1211368296693538818)], [[SBRT for spinal mets: Defining the zones of treatment](https://twitter.com/NicholasZaorsky/status/1226200897027551235?s=20)], [[For HA-WBRT, use an inclined headboard at 30 degrees to minimize dose to orbits](https://twitter.com/NicholasZaorsky/status/1234224691612672002?s=20)], [[HA-Atlas and relevant landmarks](https://twitter.com/NicholasZaorsky/status/1211365353189781506)].

ARRO: [[Arteriovenous malformation (AVM)](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/AVM.pdf)], [[Spinal Cord Glioma](https://www.astro.org/ASTRO/media/ASTRO/AffiliatePages/arro/PDFs/ARROCase_spinalglioma.pdf)], [[Trigeminal Neuralgia](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/trigeminalneuralgia.pdf)], [[Vestibular Schwannoma](https://www.astro.org/ASTRO/media/ASTRO/AffiliatePages/arro/PDFs/ARROCase_GlioMulti.pdf)], [[uveal melanoma](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/UvealMelanoma.pdf)], [[Paraganglioma of skull base](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/ParagangliomaSkullBase.pdf)]

* Early vs. Delayed PORT for treatment of low-grade gliomas [[Dhawan Cochrane Rev '20](https://www.ncbi.nlm.nih.gov/pubmed/31958162)] [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#bookmark=kix.trgp32pu40hr)
* Arteriovenous Malformations of the Brain [[Solomon NEJM '17](https://www.ncbi.nlm.nih.gov/pubmed/28489992)] [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.vktjx3razv69)
* ISRS Guidelines: SRS for Spetzler Martin GI-II AVMs [[Graffeo NS '20](https://www.ncbi.nlm.nih.gov/pubmed/32065836)]. [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.vktjx3razv69)
* Hormone deficiency (Table 1) [[Darzy Nature Rev Endo '09]](https://www.nature.com/articles/ncpendmet1051): Pituitary RT to 30-50 Gy. [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#bookmark=id.36jb6dvhxdoi)
* EANO Guidelines for the diagnosis and treatment of meningiomas [[Goldbrunner Lanc Onc '16](https://www.ncbi.nlm.nih.gov/pubmed/27599143)]. [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.cx411pj1kje8)
* Chasing your dural tail: Factors predicting local control after SRS for benign meningiomas [[Rogers IJROBP '04](https://www.redjournal.org/article/S0360-3016(05)00361-5/abstract)]. [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.ih1uwjlffapo)
* Patterns of failure after chemotherapy and involved field RT for localized germinoma [[Alapetite Neuro Onc '10](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3018943/)] [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.52geklyhbgjn)
* Pseudoprogression review article [[Brandsma Lancet '08]](https://www.sciencedirect.com/science/article/pii/S1470204508701256?via%3Dihub). [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.ii5e7lbfszey)
* GBM Patterns of failure [[Minniti RTO '10]](https://www.sciencedirect.com/science/article/pii/S0167814010005256?via%3Dihub): EORTC (T1c + 2 cm) vs. RTOG (T2 + 2 cm to 46 Gy) created to compare. [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.ii5e7lbfszey)
* SRS for management of Vestibular Schwannoma: A short review [[Buss Neurosurg Rev '20](https://www.ncbi.nlm.nih.gov/pubmed/32170501)] [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#bookmark=id.r3u1wdp25mtu)
* SRS for Pituitary Adenomas: Modern review of literature, Target Delineation, and optimal dose [[Minniti RTO '16](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5057503/)] [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#bookmark=id.4ntswz64ymcw)

## [Peds](#_xfnv5f4m7q1m)

Zaorsky [[Overview of parameningeal vs. non-parameningeal H&N](https://twitter.com/NicholasZaorsky/status/1211354704971780102) ].

ARRO: [[DIPG](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/DIPG.pdf)], [[Neuroblastoma](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/NeuroblastomaHess.pdf)], [[Wilms Tumor](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/WilmsTumor.pdf)], [[Pediatric Ependymoma](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/Ependymoma.pdf)], [[Pediatric High Risk Classical Hodgkin Lymphoma](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/PediatricHighRiskClassicalHL.pdf)], [[Pediatric Medulloblastoma Case](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/MedulloblastomaAJW.pdf), [Contour](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/Contour-MedulloblastomaAJW.pdf)].

* Review of Pediatric High-Grade Gliomas [[Jones Neuro Onc '16]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464243/) [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.gzbeagzdfcb6)
* Pediatric Hodgkin Lymphoma [[Lo and Hodgson COG Powerpoint](http://qarc.org/COG/HodgkinLymphoma.pdf)] [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.gzbeagzdfcb6)
* Pediatric High-Grade Glioma [[Perkins and Mansur COG Powerpoint](http://qarc.org/COG/HighGradeGliomas_.pdf)] [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.gzbeagzdfcb6)
* Pediatric Low-Grade Gliomas [[Mansur COG Powerpoint](http://qarc.org/COG/LowGradeGliomas_.pdf)] [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.kub5ed7dwdnv)
* Radiotherapy for Infant Brain Tumors [[Mahajan COG Powerpoint ASTRO '16](http://qarc.org/COG/BabyCNSTumors_.pdf)]
* Childhood Acute Lymphoblastic Leukemia [[Marcus COG Powerpoint](http://qarc.org/COG/AcuteLymphoblasticLeukemia_.pdf)] [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.gzbeagzdfcb6)
* RT in Patients with CNS Germ Cell Tumors [[Chuba COG Powerpoint](http://qarc.org/COG/CNSGermCellTumors_.pdf)] [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.2oxs7n6nf0a5)
* Rhabdomyosarcoma Review [[COG Powerpoint 2017](https://www.qarc.org/COG/Rhabdomyosarcoma_.pdf)]. [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.scav0ds6b7xm)
* Medulloblastoma [[Yock COG Powerpoint](http://qarc.org/COG/CNSMedulloblastoma.pdf)] [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.bky1jhsixu1a)
* Retinoblastoma [[Buchbaum COG Powerpoint](http://qarc.org/COG/Retinoblastoma_.pdf)] [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.mr633szdp2nv)
* The Double-edged Sword of Cytotoxic Therapy and PENTEC [[Constine COG Powerpoint](http://qarc.org/COG/LateEffectsInChildren.pdf)] [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.xilahm9fbnlf)
* Neuroblastoma—remembering the three physicians who described it a century ago [[Rothenberg Peds Rads '09](https://link.springer.com/article/10.1007/s00247-008-1062-z)]. [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.xm8gyp4b0wt3)
* Neuroblastoma: Excellent PowerPoint overview of protocols [[Haas-Kogan COG Powerpoint '16](https://www.qarc.org/COG/Neuroblastoma_.pdf)]. [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.xm8gyp4b0wt3)
* Wilms Tumor: Historical protocols [[Kalapurakal COG Powerpoint](http://qarc.org/COG/WilmsTumor_.pdf), [summary of NWTS trials](http://www.nwtsg.org/about/clinical_trials.html)] [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#heading=h.qy3igkd95sd6)
* Ewing Sarcoma: Local control after surgery or RT [[Ahmed IJROBP '17](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699950/), [Powerpoint](https://www.qarc.org/COG/EwingSarcoma.pdf)] [RoR](https://docs.google.com/document/d/17O0LOemBhckXGuuPBCh6u8vqBfc6lg88r46B8YctMXU/edit#bookmark=kix.x8gyf59w6m2v)
* Update on Radiation Physics in Pediatric Tumors [[Hua and Ulin COG Powerpoint '17](http://qarc.org/COG/UpdatesOnRadiationPhysicsInPediatricTumors_.pdf)]

## 

## [Constraints / Toxicity](#_xfnv5f4m7q1m)

[[Detailed constraints](https://bit.ly/RoRConstraints)] for conventional, 1, 3, 5, 8, 10, and 15 fractions regimens with protocol, QUANTEC, and clinical correlates.

* Application of Critical DVH Constraints for SBRT in NRG Radiation Therapy trials [[Ritter IJROBP '17](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754194/#R1)].
* TG-101: One/Three/Five fraction constraints per [[TG 101 AAPM '10](https://www.aapm.org/pubs/reports/rpt_101.pdf)]. [RoR](https://docs.google.com/document/d/1DnTzXxvgAsnW9eR7Br-W7ajBAFXL2IIZhvoRNcLYTK0/edit#heading=h.hjf4rn360avr)
* UK: UK/AAPM Consensus on Normal Tissue Dose constraints for SBRT [[Hanna CO '18](https://www.sciencedirect.com/science/article/pii/S093665551730434X)]. [RoR](https://docs.google.com/document/d/1DnTzXxvgAsnW9eR7Br-W7ajBAFXL2IIZhvoRNcLYTK0/edit#heading=h.hjf4rn360avr)
* HyTEC: Spinal cord dose tolerance to SBRT [[Sahgal IJROBP '19](https://www.ncbi.nlm.nih.gov/pubmed/31606528)]. [RoR](https://docs.google.com/document/d/1DnTzXxvgAsnW9eR7Br-W7ajBAFXL2IIZhvoRNcLYTK0/edit#bookmark=kix.klvlwgqivafe)
* NRG BR002 [[Pending](https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.TPS1098), [Protocol](https://www.newjerseyck.com/wp-content/uploads/2017/07/NRG-BR002-Protocol-20160222.pdf)]: Phase II/III. Standard of care and tx of symptomatic mets vs. LCT. [RoR](https://docs.google.com/document/d/1sWQwqcSH23B30CKCVOaQ2kb4D4qES6YfPqmgJYR5rnY/edit#bookmark=id.kyz8axqivny8)
* Dose-escalated radiation therapy for Pancreatic Cancer: An SIB Approach [[Koay PRO '20](https://www.ncbi.nlm.nih.gov/pubmed/32061993)]. [RoR](https://docs.google.com/document/d/13NEZCS6s13MVLixabbO2vjY73zHxJ37qE16gBbApSdY/edit#bookmark=id.cjxbbaw0ppu)
* Chronic radiation proctitis: tricks to prevent and treat [[Vanneste Int J Colorectal Dis '15]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575375/)
* LungTECH summary of RILTs for Central SBRT to the Lung (Table 3) [[Adebahr BJR '15](https://www.birpublications.org/doi/10.1259/bjr.20150036)]. [RoR](https://docs.google.com/document/d/1oKD3L5ieCk03FWU6fCnj8aiHKRPJD-q6IpjXpQCuexw/edit#bookmark=kix.hsgc4mx4om77)
* Pathophysiology of radiotherapy-induced lung injury [[Zaorsky tweet](https://twitter.com/NicholasZaorsky/status/1234226689409978369?s=20)].
* Heart V50 independently predicts for decreased OS in NSCLC [[Speirs JTO '17](https://www.jto.org/article/S1556-0864(16)31144-3/fulltext)]: Heart V50 < 25% should be standard. [RoR](https://docs.google.com/document/d/1oKD3L5ieCk03FWU6fCnj8aiHKRPJD-q6IpjXpQCuexw/edit#heading=h.k70amn44ux20)
* Cardiac morbidity: A pooled analysis of 6 dose-escalation trials for stage III NSCLC [[Wang JCO '17](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455462/)]: MHD < 20 Gy. [RoR](https://docs.google.com/document/d/1oKD3L5ieCk03FWU6fCnj8aiHKRPJD-q6IpjXpQCuexw/edit#heading=h.k70amn44ux20)
* Exploring the relationship of RT dose and length of the esophagus to weight loss in lung cancer [QS](http://www.quadshotnews.com/2020/03/the-lengths-some-people-go-to.html) [[Han PRO '20](https://www.practicalradonc.org/article/S1879-8500(20)30062-X/fulltext)]: Retro. [RoR](https://docs.google.com/document/d/1oKD3L5ieCk03FWU6fCnj8aiHKRPJD-q6IpjXpQCuexw/edit#heading=h.k70amn44ux20)

## 

## [GI](#_xfnv5f4m7q1m)

eContour [[esophageal](http://econtour.org/cases/60)], [[MRI-based upper abdominal OAR](http://econtour.org/cases/112)], [[post-op pancreas](http://econtour.org/cases/4)], [[HCC SBRT]](https://econtour.org/cases/76)

Zaorsky: [[Distance from incisors, lymph node risk, Siewert illustrations](https://twitter.com/NicholasZaorsky/status/1212012362322063360)], [[Gastric cancer LND](https://twitter.com/NicholasZaorsky/status/1212805291022180356)], [[Gastric cancer regional nodes](https://twitter.com/NicholasZaorsky/status/1212805553317122048)].

ARRO: [[Esophageal cancer case](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/Esophageal.pdf), [contour](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/EsophagealContour.pdf)].

Zaorsky: [[Pancreatic cancer resectability](https://twitter.com/NicholasZaorsky/status/1212806482774892546)], [[Why is the pancreas so difficult to treat?](https://twitter.com/NicholasZaorsky/status/1214630033798684672)] and [[is SBRT + IO the solution?](https://twitter.com/NicholasZaorsky/status/1214631434880798720)].

ARRO: [[Borderline resectable pancreatic cancer case](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/BorderlineResectablePancreatic.pdf), [contour](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/ARROContourBRPancreas.pdf)], [[Pancreas SBRT](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/ARROcasePancreasSBRT.pdf)].

Zaorsky: [[Liver anatomy explained by using your right fist](https://twitter.com/NicholasZaorsky/status/1212807418503192584)], [[Similar to the "no-fly zone" in lung cancer, there is one in liver cancer](https://twitter.com/NicholasZaorsky/status/1213175389713051652)].

ARRO: [[HCC](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/HCC.pdf)], [[HCC and SBRT](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/ARROCaseHCCSBRT.pdf)], [[Resected IHCC](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/ResectedIntrahepaticCholangiocarcinoma.pdf)], [[Unresectable IHCC](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/ARROCaseUnresectableIntrahepaticCholangiocarcinoma.pdf)].

* Radiotherapy for HCC: Ready for Prime Time? [[Bang and Dawson JHEP '20](https://www.ncbi.nlm.nih.gov/pubmed/32039361)]. [RoR](https://docs.google.com/document/d/13NEZCS6s13MVLixabbO2vjY73zHxJ37qE16gBbApSdY/edit#bookmark=id.z3gd3elgnxbv)
* Patterns of Recurrence for mCRC to liver treated with local therapy [[de Jong ASO '09](https://insights.ovid.com/pubmed?pmid=19730175)] [RoR](https://docs.google.com/document/d/13NEZCS6s13MVLixabbO2vjY73zHxJ37qE16gBbApSdY/edit#bookmark=id.oqbck3bk6zi)
* Hepatic Metastasis from CRC [[Kow JGO '19](https://www.ncbi.nlm.nih.gov/pubmed/31949948)]: Great introduction on the management of mCRC to the liver. [RoR](https://docs.google.com/document/d/13NEZCS6s13MVLixabbO2vjY73zHxJ37qE16gBbApSdY/edit#bookmark=id.1i4g32ct4820)

*This article highlights the fact that surgery is the standard of care, belittling the utility of SBRT. See our commentary above.*

* Dose-escalated radiation therapy for Pancreatic Cancer: An SIB Approach [[Koay PRO '20](https://www.ncbi.nlm.nih.gov/pubmed/32061993)]. [RoR](https://docs.google.com/document/d/13NEZCS6s13MVLixabbO2vjY73zHxJ37qE16gBbApSdY/edit#bookmark=id.cjxbbaw0ppu)
* Patterns of Failure after Pancreatic SBRT [[Zhu IJROBP '19](https://www.sciencedirect.com/science/article/pii/S0360301619301579)] [RoR](https://docs.google.com/document/d/13NEZCS6s13MVLixabbO2vjY73zHxJ37qE16gBbApSdY/edit#bookmark=id.750ku551ntwz)
* Patterns of Failure when omitting RT: ESPAC-4 [RoR](https://docs.google.com/document/d/13NEZCS6s13MVLixabbO2vjY73zHxJ37qE16gBbApSdY/edit#bookmark=id.465jo26ke0j7) [[Jones JAMA Surg ‘19](https://jamanetwork.com/journals/jamasurgery/article-abstract/2749409)] and PRODIGE-24 [RoR](https://docs.google.com/document/d/13NEZCS6s13MVLixabbO2vjY73zHxJ37qE16gBbApSdY/edit#bookmark=id.ioh3k34i1c28) [[Conroy NEJM '18](https://www.nejm.org/doi/full/10.1056/NEJMoa1809775)].
* Johns Hopkins [[Groot Ann Surg '18](https://www.ncbi.nlm.nih.gov/pubmed/28338509)]: Retro. Patterns, Timing, and Predictors of Recurrence after Whipple. [RoR](#kix.ddrz4criwqc7)

*ESPAC-4 and JHH data suggest around 2/3 of patients will relapse after an up-front Whipple procedure, and around 2/3 of first failures will be locoregional-only and/or oligometastatic liver-only. PRODIGE-24 has yet to release detailed patterns of recurrence paper.*

* Meta for RT in Pancreatic cancer [[Tchelebi Cancer '20](https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32756)]: Conventionally fractionated vs. SBRT. [RoR](https://docs.google.com/document/d/13NEZCS6s13MVLixabbO2vjY73zHxJ37qE16gBbApSdY/edit#heading=h.7msg877il527)
* Radiation Therapy for Rectal Cancer [[Tseng JGO '19](https://www.ncbi.nlm.nih.gov/pubmed/31949945)] [RoR](https://docs.google.com/document/d/13NEZCS6s13MVLixabbO2vjY73zHxJ37qE16gBbApSdY/edit#heading=h.edmjmqevmmvz)
* Rectal Cancer: Lateral Node Study Consortium [QS](http://www.quadshotnews.com/2019/09/west-side-story.html#more) [[Ogura JAMA Surg '19](https://jamanetwork.com/journals/jamasurgery/fullarticle/2736895)] [RoR](https://docs.google.com/document/d/13NEZCS6s13MVLixabbO2vjY73zHxJ37qE16gBbApSdY/edit#bookmark=id.fzfx43bpa8fc)
* Rectal Cancer: MERCURY [[Patel JCO '11](https://ascopubs.org/doi/full/10.1200/JCO.2011.34.9068), [Taylor JCO ‘14](https://www.ncbi.nlm.nih.gov/pubmed/24276776)]: ± MRI-involved CRM (tumor ≤ 1 mm from MRF). [RoR](https://docs.google.com/document/d/13NEZCS6s13MVLixabbO2vjY73zHxJ37qE16gBbApSdY/edit#bookmark=id.nal1th80tjwb)
* Local excision after preoperative CCRT for T2-T3 rectal cancers: Is the wait over? [[Dossa, Acuna and Baxter Lanc GEH '20](https://pubmed.ncbi.nlm.nih.gov/32043981/)]
* Anal Cancer: Technical aspects of radiation therapy [[Scher JGO '14](https://www.ncbi.nlm.nih.gov/pubmed/24982768)]
* Anal Cancer: UK Patterns and predictors of relapse following SIB IMRT CCRT [[Shakir IJROBP '19](https://www.ncbi.nlm.nih.gov/pubmed/31629837)]: Retro. [RoR](https://docs.google.com/document/d/13NEZCS6s13MVLixabbO2vjY73zHxJ37qE16gBbApSdY/edit#bookmark=id.rtdvsrmv2t14)
* The Landmark Series: Gallbladder Cancer [[Gamboa and Maithel ASO '20](https://pubmed.ncbi.nlm.nih.gov/32474816/)].

## [Gyn](#_xfnv5f4m7q1m)

eContour: [[post op endometrial (pelvis)](http://econtour.org/cases/53) & [(VBT)](http://econtour.org/cases/57)]; [[post op cervix](http://econtour.org/cases/55)], [[EMBRACE 2 cervix](http://econtour.org/cases/111)] and [[NRG cervix](http://econtour.org/cases/38)]; [[vaginal](https://econtour.org/cases/51)]

Zaorsky: [[Gyn staging](https://twitter.com/NicholasZaorsky/status/1219773291528884229?s=20)], [[Comparison of surgeries](https://twitter.com/NicholasZaorsky/status/1221824856834158592?s=20)], [[Gyn nodes AP](https://twitter.com/NicholasZaorsky/status/1221823861978693632?s=20), [Gyn nodes Lat](https://twitter.com/NicholasZaorsky/status/1221824276740956162?s=20)], [[Endo staging](https://twitter.com/NicholasZaorsky/status/1221829707450195975?s=20)], [[Cervical staging](https://twitter.com/NicholasZaorsky/status/1221828307068604417?s=20)], [[Cervical EBRT](https://twitter.com/NicholasZaorsky/status/1222649051235127296?s=20)], [[Cervical BT](https://twitter.com/NicholasZaorsky/status/1222648780903849986?s=20)], [[Vulvar cancer staging](https://twitter.com/NicholasZaorsky/status/1222649476386578438?s=20)].

ARRO: [[Early-stage Endometrial Cancer](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/EarlyStageEndometrial.pdf)], [[Endometrial Cancer](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/Endometrial_Vu.pdf)], [[Cervical cancer](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/CervicalCancer.pdf)], [[Operable Vulvar Cancer](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/Vulvar.pdf)], [[Vaginal Cancer](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/VaginalCancer.pdf)]

* EMBRACE II [[Pötter CTRO '18]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862686/) aims to benchmark a high level of local, nodal, and systemic control with IGABT. [RoR](https://docs.google.com/document/d/1X-MmBeoIl3IECEGIUVV4sFz_AR_s5AEQb8Xsx4szmJg/edit#bookmark=id.n9hc7b9umqu)
* Gynecologic Malignancies [[Suneja and Viswanathan Heme/Onc Clin N. Amer '20](https://www.sciencedirect.com/science/article/pii/S088985881930111X?via%3Dihub)] [RoR](https://docs.google.com/document/d/1X-MmBeoIl3IECEGIUVV4sFz_AR_s5AEQb8Xsx4szmJg/edit#heading=h.t4kv4aacj9qi)
* Management of high-risk endometrial cancer: Are we there yet? [[Randall Lancet Oncology '19](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30416-4/fulltext)]. [RoR](https://docs.google.com/document/d/1X-MmBeoIl3IECEGIUVV4sFz_AR_s5AEQb8Xsx4szmJg/edit#bookmark=id.8oe07mjrdrbn)
* Endometrial Cancer (Early Stage): See the Bayta.us [QS](http://www.quadshotnews.com/2020/02/demystify.html) [[nomogram](https://docs.google.com/document/d/1X-MmBeoIl3IECEGIUVV4sFz_AR_s5AEQb8Xsx4szmJg/edit#heading=h.m811c6vihx23)] which is newly available as of 2020! [RoR](https://docs.google.com/document/d/1X-MmBeoIl3IECEGIUVV4sFz_AR_s5AEQb8Xsx4szmJg/edit#heading=h.m811c6vihx23)
* Endometrial Cancer (Early Stage): LVSI in PORTEC 1-2 [[Bosse EJC '15](https://www.sciencedirect.com/science/article/pii/S0959804915004463?via%3Dihub)]: No LVSI vs. Focal LVSI vs. Substantial LVSI. [RoR](https://docs.google.com/document/d/1X-MmBeoIl3IECEGIUVV4sFz_AR_s5AEQb8Xsx4szmJg/edit#bookmark=id.iuwnoiy6bk4n)
* UK Definition of Margins in Vulvar Cancer [[Kortekaas IJ Gyn Path '19](https://journals.lww.com/intjgynpathology/Abstract/publishahead/Practical_Guidance_for_Measuring_and_Reporting.99077.aspx)] [RoR](https://docs.google.com/document/d/1X-MmBeoIl3IECEGIUVV4sFz_AR_s5AEQb8Xsx4szmJg/edit#heading=h.dx362qpsjtbt)
* FIGO Report: Cancer of the cervix uteri [[Bhatla IJGO '18](https://www.ncbi.nlm.nih.gov/pubmed/30306584)]
* FIGO Report: Cancer of the Vagina [[Adams and Cuello, IJGO '18](https://www.ncbi.nlm.nih.gov/pubmed/30306589)] [RoR](https://docs.google.com/document/d/1X-MmBeoIl3IECEGIUVV4sFz_AR_s5AEQb8Xsx4szmJg/edit#heading=h.ngxza69hnb07)
* FIGO Report: Cancer of the Vulva [[Rogers and Cuello IJGO '18](https://www.ncbi.nlm.nih.gov/pubmed/30306583)] [RoR](https://docs.google.com/document/d/1X-MmBeoIl3IECEGIUVV4sFz_AR_s5AEQb8Xsx4szmJg/edit#heading=h.k19a41x9sid8)

## 

## [Non-Prostate GU](#_xfnv5f4m7q1m)

Zaorsky: [[MGH/Shipley regimen for CCRT in bladder preservation](https://twitter.com/NicholasZaorsky/status/1219387727524827138?s=20)], [[urinary diversion options](https://twitter.com/NicholasZaorsky/status/1217887052269789185?s=20)], [[cystectomy](https://twitter.com/NicholasZaorsky/status/1217886710794784770?s=20)].

Zaorsky: [[Staging of kidney cancer](https://twitter.com/NicholasZaorsky/status/1219390416388313090?s=20)]

Zaorsky: [[Doses and fields for CS I and II seminoma](https://twitter.com/NicholasZaorsky/status/1219395983844478976?s=20)], [[failure patterns](https://twitter.com/NicholasZaorsky/status/1219395565936615430?s=20)], [[at-risk sites](https://twitter.com/NicholasZaorsky/status/1219392914285047809?s=20)]

ARRO: [[Bladder cancer](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/Bladder.pdf)]

eContour [[testicular dog-leg](http://econtour.org/cases/62)]

* IROCK: SRS as a Treatment Option for Renal Tumors in the Solitary Kidney [[Correa J Uro '19](https://www.auajournals.org/doi/10.1097/JU.0000000000000111)]. [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.lagazxl9a1jc)
* Bladder: [Pooled RTOG analysi](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239302/)s of bladder preservation therapy [[Mak JCO '14]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239302/) [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.umirepomlwp7)
* Bladder: Christodouleas [[IJROBP '16]](https://www.sciencedirect.com/science/article/pii/S0360301616000365?via%3Dihub): Pelvic failure estimates after Radical Cystectomy. [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.p72dqbs603jv)
* Bladder: Pooled RTOG analysis [[Efstathiou JCO '09](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2734419/)]: Late effects of bladder preservation do not appear prohibitive. [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#bookmark=id.bn94lqj5cygv)
* Bladder: Meta of BC2001 and Bcon trials [[Porta ASTRO ‘19](https://www.eventscribe.com/2019/ASTRO/fsPopup.asp?Mode=presInfo&PresentationID=559471)]: 64/32 vs. 55/20.
* Testicular: [BC [Kollmannsberger JCO '15]](http://ascopubs.org/doi/abs/10.1200/JCO.2014.56.2116?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed): Retro. Surveillance with salvage for relapse. [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.xw4igsc5rhtc)
* Testicular: Radiotherapy Treatment Planning [[Wilder IJROBP '12]](https://www.sciencedirect.com/science/article/pii/S036030161200096X?via%3Dihub) [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.pjkpjb9ykwkx)
* Testicular: Patterns of failure depends on the modality of treatment [[Mead JNCI '11](https://academic.oup.com/jnci/article/103/3/241/2517208)] [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.59pvmzpcgttf)

## 

## [GU](#_xfnv5f4m7q1m)

eContour training module [[Prostate Fossa](https://econtour.org/fundamentals)], [[Intact prostate](https://econtour.org/fundamentals)]

eContour cases [[post-prostatectomy](http://econtour.org/cases/35)], [[intact conventional prostate](http://econtour.org/cases/34)] and [[intact hypofractionated prostate](http://econtour.org/cases/109)].

Zaorsky: [[Obesity and prostate cancer: Weighing the evidence](https://twitter.com/NicholasZaorsky/status/1226862227078164480?s=20)], [[PTV advantage of brachytherapy](https://twitter.com/NicholasZaorsky/status/1217886128193376257?s=20)], [[Risk of nodal involvement](https://twitter.com/NicholasZaorsky/status/1215670456130441216?s=20)], [[importance of full/empty bladder](https://twitter.com/NicholasZaorsky/status/1215669203887382531?s=20)], [[Prostate cancer failure patterns after prostatectomy](https://twitter.com/NicholasZaorsky/status/1228330423283068929?s=20)]

ARRO: [[HDR prostate brachytherapy](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/ARROCaseProstatebrachy.pdf)].

* Excellent Prostate LDR review article [[Stish TAU '18](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043740/#r22)]. [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.13ndhxnku715)
* Excellent Prostate HDR monotherapy review article [[Demanes BT '14](https://www.sciencedirect.com/science/article/pii/S1538472114005054)]. [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.13ndhxnku715)
* HDR-BT in the treatment of prostate cancer [[Mendez and Morton TAU '18](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043748/)] [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.13ndhxnku715)
* Optimal therapy for localized PrCa: the recreation of the self-fulfilling prophecy w Combo BT? [[Spratt/Carroll JCO '18](https://ascopubs.org/doi/full/10.1200/JCO.2018.78.6236)] [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#bookmark=kix.6xx8kqrbj7i7)
* Long term ADT with less clear additional benefit after 24 mos when added to RT [[Williams IJROBP '11](https://www.sciencedirect.com/science/article/pii/S0360301609036177?via%3Dihub)]. [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#bookmark=kix.hi05q7uplhwx)
* The natural history of progression of PSA recurrence after EBRT [[Zumsteg Eur Urol '15](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002994/)]: 75.6-86.4 Gy [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.gdeho2qslf5e)
* MSKCC Patterns of Recurrence after EBRT to Prostate [[Zumsteg JUro '15](https://www.jurology.com/article/S0022-5347(15)04327-X/fulltext)]: Retro. Median 81 Gy/45 (1.8 Gy). [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.p72dqbs603jv)
* The natural history of progression of PSA recurrence after RP [[Antonarakis BJU Int '13](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204323/)] [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.gdeho2qslf5e)
* Stephenson Nomogram [[JCO '07]](http://ascopubs.org/doi/full/10.1200/JCO.2006.08.9607): Predicting outcomes for SRT. bcPFS only. [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.i7kgh6aebogz)
* Tendulkar Nomogram [[JCO '16]](http://ascopubs.org/doi/abs/10.1200/JCO.2016.67.9647): SRT ± ADT. Adds DMFS data to Stephenson.[RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.i7kgh6aebogz)
* Campbell Nomogram [[ASTRO '19](https://www.eventscribe.com/2019/ASTRO/fsPopup.asp?Mode=presInfo&PresentationID=559444)]: SRT ± ADT. Adds PSA-DT and post-op initial PSA value data to Tendulkar. [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.i7kgh6aebogz)
* European Association of Urology Validation of bcF Risk Groups [[Tilki Euro Uro '19](https://www.europeanurology.com/article/S0302-2838(19)30202-7/fulltext)]: Retro. HR vs. LR. [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.i7kgh6aebogz)
* Patterns of recurrence after prostate bed RT [[Brand RTO '19](https://www.thegreenjournal.com/article/S0167-8140(19)33091-9/fulltext)]: Retro. [RoR](https://docs.google.com/document/d/1j15zXLBPWwqty60Slm2jnHEiqaoT2iw5Gapp4iMWJsw/edit#heading=h.p72dqbs603jv)
* SBRT Meta for LR and IR (Figure 2 - excellent breakdown of all modalities) [[Kishan JAMA Netw Open '19](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2723641)]: 33.5-40/4-5.
* CHHiP Acute Toxicity (Figure 4 - time points) [[Dearnaley Lanc Onc '16](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961874/)]: Noninferiority. 74/37 vs. 57/19 vs. 60/20.

## [H&N, Thyroid](#_xfnv5f4m7q1m)

eContour: [[OARs](http://econtour.org/cases/72), [Choi Rad Onc '14](https://www.ncbi.nlm.nih.gov/pubmed/25499048), [Brouwer RTO '15](https://www.sciencedirect.com/science/article/pii/S0167814015004016?via%3Dihub)], [[Maxillary sinus](http://econtour.org/cases/37)], [[Nasopharynx](http://econtour.org/cases/2)], [[Hard palate / Adenoid cystic (V2)](http://econtour.org/cases/19)], [[Parotid (VII)](http://econtour.org/cases/30)], [[Buccal mucosa](http://econtour.org/cases/28)], [[Oral cavity](http://econtour.org/cases/3)], [[Oropharynx (ipsilateral neck)](http://econtour.org/cases/31)], [[Base of tongue](http://econtour.org/cases/1)], [[Supraglottic larynx](http://econtour.org/cases/18)], [[Early stage glottic larynx](http://econtour.org/cases/5)], [[Subglottic larynx](http://econtour.org/cases/27)], [[Pyriform sinus](http://econtour.org/cases/24)], [[Thyroid](http://econtour.org/cases/21)], [[Cancer of unknown primary](http://econtour.org/cases/6)].

Zaorsky: [[Counting teeth made easy](https://twitter.com/nicholaszaorsky/status/1211453658950488066?s=21)], [[Otalgia](https://twitter.com/NicholasZaorsky/status/1211452057573613569)], [[Neuroforamen on axial CT scans](https://twitter.com/NicholasZaorsky/status/1211362859621502976)], [[Nasopharyngeal cancer staging](https://twitter.com/NicholasZaorsky/status/1211454984518295558)], [[Types of laryngeal surgeries](https://twitter.com/NicholasZaorsky/status/1211456862958358528)], [[Types of neck dissections](https://twitter.com/NicholasZaorsky/status/1211383604523257858)], [[Anatomy of lateral view on cranial x-ray](https://twitter.com/NicholasZaorsky/status/1211377339113840647)].

ARRO: [[Early stage glottic larynx](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/ARROCaseEarlyStageGlottic.pdf)], [[Esthesioneuroblastoma](https://www.astro.org/ASTRO/media/ASTRO/AffiliatePages/arro/PDFs/ARROCase_Esthesioneuroblastoma.pdf)], [[Nasopharynx](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/Nasopharynx.pdf)], [[Parotid Adenoid Cystic with PNI](https://www.astro.org/ASTRO/media/ASTRO/AffiliatePages/arro/PDFs/ARROCase_HN_PerineuralInvasion.pdf)], [[Merkel cell of extremity](https://www.astro.org/ASTRO/media/ASTRO/AffiliatePages/arro/PDFs/ARROCase_MerkelCell.pdf)], [[Cancer of unknown primary](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/OccultPrimaryofHN.pdf)], [[oligometastatic HPV+ OP](https://www.astro.org/ASTRO/media/ASTRO/AffiliatePages/arro/PDFs/ARROcase_Oligomet_HN.pdf)], [[OP case](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/BOTCase.pdf%5C), [OP contour](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/BOTContour.pdf), [OP HPV+ de-escalation](https://www.astro.org/ASTRO/media/ASTRO/AffiliatePages/arro/PDFs/ARROCase_HPV_OPX.pdf)], [[Palliative advanced non-melanoma skin cancer](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/PalliativeRONonmelanoma.pdf)], [[Paranasal sinus cancer](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/SNUC.pdf)], [[Salivary gland tumors](https://www.astro.org/ASTRO/media/ASTRO/AffiliatePages/arro/PDFs/ARROCase_SalivaryGlandTumors.pdf)], [[Supraglottic larynx (post-tracheostomy) case](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/SupraglotticLarynx.pdf), [contour](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/ARROContourSupraglottic.pdf)].

* HNCIG Consensus Guidelines for PORT in complex cutaneous SqCC of the H&N [[Porceddu IJROBP '20](https://www.ncbi.nlm.nih.gov/pubmed/32289475)] [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#bookmark=id.bu7ucgcgwtdr)
* Delineation of neck node levels for head and neck tumors [[Grégoire RTO '13](https://www.sciencedirect.com/science/article/pii/S0167814013005148?via%3Dihub), [Radiopaedia Interactive atlas](https://radiopaedia.org/cases/lymph-node-levels-of-the-head-and-neck-annotated-ct?lang=us)] [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#heading=h.rzy8rvsdopq0)
* Delineation of CTVp in H&N cancer [[Grégoire Rad Onc '18](https://www.sciencedirect.com/science/article/pii/S0167814017326567)] [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#bookmark=kix.kqkdc6ce2kxe)
* Delineation of CTVp and CTVn in the primary RT of OC, OP, hypopharyngeal and laryngeal [[Grégoire Oral Onc '18](https://www.ncbi.nlm.nih.gov/pubmed/30527228)] [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#bookmark=id.jotgn0jfcaxd)
* Selection of lymph node target volumes of neck node levels for definitive H&N RT [[Biau RTO '19](https://www.sciencedirect.com/science/article/pii/S0167814019300234)]. [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#heading=h.rzy8rvsdopq0)
* Practical clinical guidelines for contouring the trigeminal nerve (V) and its branches [[Atlas (Supplement) Biau RTO '19](https://www.thegreenjournal.com/article/S0167-8140(18)33458-3/abstract)] [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#heading=h.q4gl8dq6tbz5)
* PNI in Head and Neck Cancer [[Bakst IJROBP '19](https://www.sciencedirect.com/science/article/pii/S0360301618341750)]: How to chase nerves, recommended doses. [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#heading=h.q4gl8dq6tbz5)
* T4 Laryngeal Cancer with Good Function: Should we be Reluctant to Treat Without Surgery? [[Beitler IJROBP '18](https://www.redjournal.org/article/S0360-3016(18)30531-5/fulltext)]. [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#bookmark=id.9vi261r1ok6d)
* Incidence and Mortality Risk Spectrum across aggressive variants of Papillary Thyroid Cancer [QS](http://www.quadshotnews.com/2020/03/pappy.html) [[Ho JAMA Onc '20](https://jamanetwork.com/journals/jamaoncology/fullarticle/2761983)] [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#heading=h.o2tfl8pl8yjb)
* Head and Neck Cancer [[Chow NEJM '19](https://www.ncbi.nlm.nih.gov/pubmed/31893516)]: Excellent Review Article with Interactive Graphic for Treatment Options. [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#heading=h.yc56opxk661h)
* Characteristics and Management of Cancer of Unknown Primary [[Galloway JCO '15](http://ascopubs.org/doi/abs/10.1200/jco.2015.61.0063)] [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#heading=h.wcda29odiys8)
* 2b or not 2b? [[Dziegielewski Cancer '19](https://www.ncbi.nlm.nih.gov/pubmed/31873950)]: Selective Neck Dissection ± Level 2b dissection on the dominant-hand side. [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#bookmark=id.m4be3b3op7yd)
* Guidelines for delineation of OARs for NPX Cancer (Scrollable atlas in Supplementary) [[Sun RTO '14](https://www.ncbi.nlm.nih.gov/pubmed/24721546)]. [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#heading=h.jzpa1pl26apt)
* Association of CCRT Regimens with OS in pts with NPC [QS](http://www.quadshotnews.com/2019/10/tsa-postcheck.html) [[Zhang JAMA ‘19](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2753250)]: Meta. CCRT→ CTX vs. CTX→ CCRT [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#heading=h.7thk137pajfm)
* Factors associated with Severe Late Toxicity after CCRT [[Machtay JCO '08]](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911537/): Review of RTOG 91-11, 97-03, and 99-14. [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#bookmark=id.oalwx2995ok0)
* Long term aspects of QoL in H&N cancer patients treated with IMRT [[Abel ARO '20](https://www.ncbi.nlm.nih.gov/pubmed/32051896)] [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#bookmark=id.ak3s3ce5sict)
* Assessment of the Rate of Skip Mets to Neck Nodal Level IV in cN0 OC SqCC [QS](http://www.quadshotnews.com/2019/05/level-snore.html) [[Warshavsky JAMA H&N '19](https://jamanetwork.com/journals/jamaotolaryngology/article-abstract/2733034)] [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#bookmark=id.uaoykhjhhnc2)
* UK Evaluation of LRR Patterns for OC SqCC [[Waldram Clin Onc '19](https://www.ncbi.nlm.nih.gov/pubmed/31668378)]: Retro. Surgery→ PO-IMRT ± concurrent chemo. [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#heading=h.d6be4rtf20e3)
* ORATOR/TORS [QS](http://www.quadshotnews.com/2019/08/because-tors.html) [[Protocol (Appendix)](https://www.sciencedirect.com/science/article/pii/S1470204519304103?via%3Dihub)]: Phase II. HPV+ OP. TORS/LND ± PO(C)RT vs. Definitive (CC)RT. [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#bookmark=kix.6jzqx268nabc)

## 

## [Skin](#_xfnv5f4m7q1m)

Zaorsky: [[Otalgia](https://twitter.com/NicholasZaorsky/status/1211452057573613569)], [[Neuroforamen on axial CT scans](https://twitter.com/NicholasZaorsky/status/1211362859621502976)]

ARRO: [[Palliative advanced non-melanoma skin cancer](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/PalliativeRONonmelanoma.pdf)]

* MOHS for Melanoma [QS](http://www.quadshotnews.com/2019/04/gimme-mohs.html) [[Demer Derm Surg '19](https://insights.ovid.com/pubmed?pmid=30550523)]: Retro. WLE (SM 10-15mm) vs. MOHS (SM 2-3mm). [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#heading=h.yluty9ypgoc0)
* Mitotic rate > 5/mm2 has the greatest impact on Melanoma CNS metastasis [[Haydu JCO '20](https://www.ncbi.nlm.nih.gov/pubmed/31990608)]: Stage III melanoma. [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#bookmark=id.u82z0qfnatzt)
* Meta for BCC and SqCC [[Lee Cancer '20](https://www.ncbi.nlm.nih.gov/pubmed/31355928)]: EBRT vs. Conventional excision vs. MOHS vs. BT. [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#bookmark=id.r0k2kvw5hgyu)
* Merkel Cell Carcinoma: The Past, the Present, and the Future [[Erovic J Skin Ca '13](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652192/)] [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#heading=h.v5hmtep3hh5d)
* Merkel Cell Carcinoma: An Update and Immunotherapy [[Uchi Frontiers in Oncology '18](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845720/)] [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#heading=h.v5hmtep3hh5d)
* Adjuvant Radiotherapy for Merkel Cell Carcinoma [[Petrelli RTO '19](https://www.sciencedirect.com/science/article/pii/S0167814019300866?via%3Dihub)] [RoR](https://docs.google.com/document/d/1STZuiggtbkDIuuNMpDVSsqT2KMyp1017y8qV5Gz_GGc/edit#heading=h.v5hmtep3hh5d)

## [Heme](#_xfnv5f4m7q1m)

ARRO: [[Pediatric High Risk Classical HL](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/PediatricHighRiskClassicalHL.pdf)], [[DLBCL case](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/HeadNeckDLBCL-NGT.pdf), [contour](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/HeadNeckDLBCL-NGT-Contour.pdf)], [[Early-stage favorable classic HL](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/HodgkinsCQ.pdf)], [[Orbital MALT](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/Orbital.pdf)], [[Solitary Plasmacytoma](https://www.astro.org/ASTRO/media/ASTRO/AffiliatePages/arro/PDFs/ARROcase_Plasmacytoma.pdf?utm_source=MagnetMail&utm_medium=email&utm_term=jeff.ryckman@gmail.com&utm_content=ARROgram%5F042320&utm_campaign=ARROgram%20April%20Monthly%20Announcement)]

eContour: [[NLPHL: axillary](http://econtour.org/cases/40)], [[ES-F HL](http://econtour.org/cases/45)], [[ES-U HL](http://econtour.org/cases/39)], [[MALT: conjunctiva](http://econtour.org/cases/99)], [[MALT: lacrimal](http://econtour.org/cases/98)], [[MALT: parotid](http://econtour.org/cases/46)], [[FL: inguinal](http://econtour.org/cases/41)]

* [[ILROG Guidelines](https://www.ilrog.org/main-st)] website.
* ISRT in Adult Lymphomas: An Overview of ILROG Guidelines[[Wirth IJROBP '20](https://www.ncbi.nlm.nih.gov/pubmed/32272184)] [RoR](https://docs.google.com/document/d/1gKy2Hpx7FxInjOpKIBkTFJWpqhJ3I-gSXz9eRwq-NSY/edit#bookmark=id.8tnt1mw76a6)
* Making Every Single Gray Count: ISRT Delineation Guidelines for Heme Malignancies (Atlas) [[Dabaja IJROBP '20](https://www.ncbi.nlm.nih.gov/pubmed/31928641)]. [RoR](https://docs.google.com/document/d/1gKy2Hpx7FxInjOpKIBkTFJWpqhJ3I-gSXz9eRwq-NSY/edit#bookmark=id.gq1ic3qggdvh)
* PET Guided Therapy for ES-Hodgkin Lymphoma: Are we Positive about a Negative Interim Scan? [[Bakst IJROBP '20](https://www.ncbi.nlm.nih.gov/pubmed/32142868)]. [RoR](https://docs.google.com/document/d/1gKy2Hpx7FxInjOpKIBkTFJWpqhJ3I-gSXz9eRwq-NSY/edit#bookmark=id.on80n14yxoeb)
* Chemo only in early-stage Hodgkin lymphoma: More relapses but "same" (or possibly worse) OS [[Yahalom CHMR '14](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180027/)] [RoR](https://docs.google.com/document/d/1gKy2Hpx7FxInjOpKIBkTFJWpqhJ3I-gSXz9eRwq-NSY/edit#bookmark=kix.td7evjrssk54)
* TSEBT in MF: A shift towards lower dose? [[Chowdhary Chin Clin Onc '19](https://www.ncbi.nlm.nih.gov/pubmed/30525748)] [RoR](https://docs.google.com/document/d/1gKy2Hpx7FxInjOpKIBkTFJWpqhJ3I-gSXz9eRwq-NSY/edit#heading=h.863hkgmxw2d)
* Patterns of failure following CAR-T therapy [[Figura ASTRO '19](https://www.eventscribe.com/2019/ASTRO/fsPopup.asp?Mode=presInfo&PresentationID=558932)]

## [Rad Phys and Rad Bio](#_xfnv5f4m7q1m)

* Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer [[Sia FCDB '20](https://www.ncbi.nlm.nih.gov/pubmed/32117972)]. [RoR](https://docs.google.com/document/d/1WGO0ms-uutSies98CoG31NpD2aBpzX8ffUS5auOgYW4/edit#heading=h.crcfeybopnjo)
* Cellular Pathways in Response to Ionizing RT and Their Targetability for Tumor Radiosensitization [[Maier IJMS '16](https://www.mdpi.com/1422-0067/17/1/102)]. [RoR](https://docs.google.com/document/d/1WGO0ms-uutSies98CoG31NpD2aBpzX8ffUS5auOgYW4/edit#heading=h.crcfeybopnjo)
* Figure 1: Induction of cell cycle arrest after irradiation.
* Figure 2: Cell death pathways after irradiation.
* Figure 3: AKT1 as a proliferation and anti-apoptotic factor.
* Figure 4: Induction of DNA repair by EGFR signaling.

## [Sarcoma / Musculoskeletal](#_xfnv5f4m7q1m)

eContour: [[Lower extremity STS](http://econtour.org/cases/115)]

ARRO: [[Retroperitoneal Sarcoma](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/ARROcaseRPSarcoma.pdf)], [[Sarcoma](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/ARROCaseSarcoma.pdf)]

* RT in Retroperitoneal Sarcoma Management [[Haas JSO '17](https://onlinelibrary.wiley.com/doi/pdf/10.1002/jso.24892)]. [RoR](https://docs.google.com/document/d/1eal6YYRhPGwh4_R5MPQdioLZLapJBSIAXZjuO3IeU6M/edit#heading=h.oejspbehx9b8)
* Desmoid Tumor Working Group [[Eur J Cancer '20](https://www.ncbi.nlm.nih.gov/pubmed/32004793)]: The Management of Desmoids: A Global consensus-based guideline. [RoR](https://docs.google.com/document/d/1eal6YYRhPGwh4_R5MPQdioLZLapJBSIAXZjuO3IeU6M/edit#bookmark=id.szd5ds5w88is)
* Heterotopic ossification after hip arthroscopy (Review Article) [[Amar J Hip Preservation Surg '15](https://academic.oup.com/jhps/article/2/4/355/2379457)]. [RoR](https://docs.google.com/document/d/1eal6YYRhPGwh4_R5MPQdioLZLapJBSIAXZjuO3IeU6M/edit#heading=h.822mr8dchlbg)

## [Thorax](#_xfnv5f4m7q1m)

ARRO: [[Thymoma](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/Thymoma.pdf)], [[Management of Chest Wall Toxicity After SBRT](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/ChestWallToxicity.pdf)], [[Central Lung Early Stage NSCLC](https://www.astro.org/ASTRO/media/ASTRO/AffiliatePages/arro/PDFs/ARROCase_SABR_Lung_EarlyStage.pdf)], [[NSCLC](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/NSCLCIIIB.pdf)], [[Resectable LA-NSCLC](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/Resectablelung.pdf)], [[Small Cell Lung Cancer](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/ARROcase/Content_Pieces/ARROCaseSmallCell.pdf)], [[Thymoma](https://www.astro.org/uploadedFiles/_MAIN_SITE/Affiliate/ARRO/Resident_Resources/Educational_Resources/Content_Pieces/Thymoma.pdf)].

eContour [[Thoracic OARs and lobar anatomy](https://econtour.org/cases/89), [Kong IJROBP '11](https://www.ncbi.nlm.nih.gov/pubmed/20934273)], [[PORT for pN2](https://econtour.org/cases/96)].

Zaorsky: [[LN stations in lungs](https://twitter.com/NicholasZaorsky/status/1211640873634664453)].

* RT for Lung Cancer Collaborative Group for SBRT without pathology [[Berman TLCR '19](http://tlcr.amegroups.com/article/view/26375/19723)]. [RoR](https://docs.google.com/document/d/1oKD3L5ieCk03FWU6fCnj8aiHKRPJD-q6IpjXpQCuexw/edit#heading=h.canzrk46c7jc)
* ASTER [[Annema JAMA '10](https://jamanetwork.com/journals/jama/fullarticle/186959)]: ± EUS-EBUS→ Surgical staging. Central disease has 15% N2 FNR (!!) for PET + EBUS [RoR](https://docs.google.com/document/d/1oKD3L5ieCk03FWU6fCnj8aiHKRPJD-q6IpjXpQCuexw/edit#bookmark=id.uvpyhpg46hix)
* Mediastinal Nodal Clearance (MNC) with high dose CCRT is associated with a *doubling* in OS [[Vyfhuis IJROBP '18](https://www.sciencedirect.com/science/article/pii/S0360301618302505?via%3Dihub#fig1)] [RoR](https://docs.google.com/document/d/1oKD3L5ieCk03FWU6fCnj8aiHKRPJD-q6IpjXpQCuexw/edit#bookmark=id.tf2fioskkctm)
* ES-NSCLC: LungTECH summary of RILTs for Central SBRT to the Lung (Table 3) [[Adebahr BJR '15](https://www.birpublications.org/doi/10.1259/bjr.20150036)]. [RoR](https://docs.google.com/document/d/1oKD3L5ieCk03FWU6fCnj8aiHKRPJD-q6IpjXpQCuexw/edit#bookmark=kix.hsgc4mx4om77)
* ES-NSCLC: Validation of RTOG 0813 PBT constraints for non-pneumonitis toxicity (NPT) [[Manyam IJROBP '20](https://www.ncbi.nlm.nih.gov/pubmed/31987965)] [RoR](https://docs.google.com/document/d/1oKD3L5ieCk03FWU6fCnj8aiHKRPJD-q6IpjXpQCuexw/edit#bookmark=id.vpyexbt32q11)
* ES-NSCLC: Safety and Effectiveness of SABR for ultra-central lung lesions [Chen JTO '19] [RoR](https://docs.google.com/document/d/1oKD3L5ieCk03FWU6fCnj8aiHKRPJD-q6IpjXpQCuexw/edit#bookmark=id.iuao5xsxaskw)
* ES-NSCLC: RTOG 0236 Patterns of Failure [[Timmerman JCO '18](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117101/)]: Phase II. The equivalent of 54/3 biw. [RoR](https://docs.google.com/document/d/1oKD3L5ieCk03FWU6fCnj8aiHKRPJD-q6IpjXpQCuexw/edit#bookmark=id.a7j9wvgpo9h0)
* LA-NSCLC: PACIFIC Patterns of Failure [[](https://www.nejm.org/doi/full/10.1056/NEJMoa1709937)[Raben ASTRO LBA6 ‘19](https://www.astro.org/ASTRO/media/ASTRO/Meetings%20and%20Education/PDFs/AM19/2019-LBAs.pdf)]: NACCRT (54-66 Gy) ± Durva q2w up to 1y. [RoR](https://docs.google.com/document/d/1oKD3L5ieCk03FWU6fCnj8aiHKRPJD-q6IpjXpQCuexw/edit#bookmark=id.xpwgdlid9n6k)
* Differential Relapse Patterns for NSCLC Subtypes [[McAleese Clin Onc '19](https://www.ncbi.nlm.nih.gov/pubmed/31351746)]: Retro. AC vs. SqCC. [RoR](https://docs.google.com/document/d/1oKD3L5ieCk03FWU6fCnj8aiHKRPJD-q6IpjXpQCuexw/edit#heading=h.12dcu6uefto4)
* What is the role of RT for ES-SCLC in the immunotherapy era? [QS](http://www.quadshotnews.com/2019/07/chest-bump.html) [[Nesbit TLCR '19](http://tlcr.amegroups.com/article/view/28932)]. [RoR](https://docs.google.com/document/d/1oKD3L5ieCk03FWU6fCnj8aiHKRPJD-q6IpjXpQCuexw/edit#bookmark=id.snu066265ta7)
* Oligo Review of NSCLC Oligometastases [Giulani IJROBP '20]. [RoR](https://docs.google.com/document/d/1CfbqB4YnaPB8U3r2LykLv2v3bRLJyYQV0tvX4Js2Mog/edit#heading=h.sfi9w935mota)

## [Misc](#_xfnv5f4m7q1m)

MRI basics for Radiation Oncologists [[van der Heide CTRO '19](https://www.ncbi.nlm.nih.gov/pubmed/31341980)]

The transformation of radiation oncology using real-time magnetic resonance guidance: A review [[Hall EJC '19](https://www.ncbi.nlm.nih.gov/pubmed/31614288)]